BioSpace News Archive

DNAnexus, Inc. , the provider of the Precision Health Data Cloud, and TMA Precision Health today announced a collaboration to advance basic and translational research for patients who have a rare disease.

Biotricity Inc., a leading medical diagnostic and consumer healthcare technology company, announced the expanding development of its future Cardiac AI Cloud platform.

Centene Corporation (NYSE: CNC) issued a reminder today that it will release its 2023 fourth quarter and full year financial results at approximately 6 a.m. ET on Tuesday, February 6, 2024, and host a conference call at 8:30 a.m. ET to review the results.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024.

Taiho Oncology, Inc. announces publication of the final results from the pivotal ASCERTAIN clinical trial of fixed-dose oral decitabine and cedazuridine (INQOVI®) compared to intravenous decitabine in adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).

Aytu BioPharma, Inc. today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.

BostonGene today announced a master agreement with Duke University School of Medicine to collaborate on multiple research projects across lung cancer, gastrointestinal, genitourinary and skin cancers.

City of Hope announced the appointment of Kristin Higgins, M.D., as the chief clinical officer at City of Hope Cancer Center Atlanta.

AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.

Inhibrx, Inc. and Sanofi announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.